Descovy-based HIV products
In the third quarter, Gilead Sciences’ (GILD) Descovy-based HIV product sales were $2.41 billion, which is a YoY rise of 50.81% and a sequential rise of 12.44%.
Genvoya’s sales hit $1.17 billion in the third quarter, which is a YoY rise of 19.03% and a sequential rise of 1.38%. In the third quarter, Odefsey’s total sales hit $423 million, which is YoY growth of 42.90% and a sequential rise of 9.87%. Descovy saw sales of $406 million, which is a YoY rise of 28.48%. Biktarvy’s total sales were $386 million, while the company recognized revenues of $22 million from the sale of Symtuza in the third quarter.
Biktarvy’s growth trends
On February 7, 2018, Gilead Sciences issued a press release announcing FDA approval for Biktarvy for HIV-1 infection. In the third quarter, Biktarvy saw sales of $375 million from the US market.
According to the company’s third-quarter earnings conference call, Biktarvy has emerged as the leading HIV drug for both treatment-naïve as well as switch patients. While 85% of Biktarvy’s prescriptions in the US market were attributable to patients switching from other HIV therapies, 25% of these patients were switching from dolutegravir-based regimens to Biktarvy. According to the company’s third-quarter earnings conference call, Biktarvy is expected to surpass Genvoya in terms of product sales within the first year of launch and emerge as the most successful commercial launch in the HIV area.
On June 25, Gilead Sciences issued a press release announcing European Commission approval for Biktarvy in the HIV-1 indication. According to the company’s investor presentation, Biktarvy has already become one of the five leading prescribed regimens in Germany both for treatment-naïve patients as well as those switching from other active regimens. Gilead Sciences estimates that almost one-third of Biktarvy’s switch patients in Germany were previously on HIV regimens containing dolutegravir.
According to the company’s investor presentation, Biktarvy has also been granted fast-track status in France. The company expects to launch this drug in France by the end of 2018.
In the next article, we’ll discuss growth trends for Gilead Sciences’ HIV prophylaxis business in greater detail.